RVTY Q3 Earnings Beat Estimates on Life Sciences Strength, '26 View Up

What happened: Revvity, Inc. RVTY reported third-quarter 2026 adjusted EPS of $1.38 and revenue of $728.9 million, both above Zacks Consensus Estimates, and raised its full-year 2026 pro forma outlook. Key numbers: Adjusted EPS $1.38, up 16.9% year over year, beating the $1.29 Why it matters: Results benefited from broad-based growth, improving pharmaceutical and biotech demand and operating efficiencies. The raised 2026 view excludes the China Immunodiagnostics business, which accounted for approximately 6% of 2025 revenues, with the divestiture expected to close by the end of 2027. Market: +0.1% today ($79.57), -8.9% YTD, 1.1x vol — as of 21:31 UTC Verified: Q3_2026 (Nov 5) revenue $796.2M vs $796.2M est; next print ~Feb 4 Coverage: 3 outlets in 24h

Revvity, Inc. RVTY reported third-quarter 2026 adjusted EPS of $1.38 and revenue of $728.9 million, both above Zacks Consensus Estimates, and raised its full-year 2026 pro forma outlook.

Results benefited from broad-based growth, improving pharmaceutical and biotech demand and operating efficiencies. The raised 2026 view excludes the China Immunodiagnostics business, which accounted for approximately 6% of 2025 revenues, with the divestiture expected to close by the end of 2027. Market: +0.1% today ($79.57), -8.9% YTD, 1.1x vol — as of 21:31 UTC Verified: Q3_2026 (Nov 5) revenue $796.2M vs $796.2M est; next print ~Feb 4